Oligonucleotide erapeutics Society c/o Event In ations, Inc. 4377 Newport Avenue San Diego, CA 92 7, USA Phone: (619) 795-9458 Fax: (619) 923-3230 Email: [email protected] erapeutics.org Find us on: Facebook page opens in new window Twitter page opens in new window YouTube page opens in new window Linkedin page opens in new window. Oligonucleotide erapeutics Society. 2,988 likes. 4 talking about. A nonprofit forum to foster academia and industry based research and development of oligonucleotide erapeutics.Followers: 3K. e highly regarded OTS Annual Meeting draws experts from all over e world for cross-disciplinary exchange spanning expertise in chemistry and delivery Past Annual Meetings. Annual Meeting. Agenda. Abstracts. Sponsors & Exhibitors. Annual Meeting. Meeting Overview. Meeting Report. Ad Winners. Photo Gallery. Video Gallery. Annual Meeting. Meeting Overview. Ad Winners. Abstracts. Meeting Videos. Meeting Notes. Photo Gallery. 5 Annual Oligonucleotide & Precision erapeutics Congress: Join us is Fall (Dates: ober 19-21, Location: VIRTUAL) Bringing toge er leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers, OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide erapies roughout e drug development process. e Oligonucleotide erapeutics Society was founded to foster e development of el oligonucleotide-based medicines. For many OTS members, achieving at aim involves following a course at starts wi understanding basic biological mechanisms at oligonucleotide erapeutics will tap into—in particular, e production and function of. 13 Annual Meeting of e Oligonucleotide erapeutics Society Date 24-09- to 27-09- Location Bordeaux (France) Description. Join leading experts in e field during is ree and a half day meeting featuring e latest developments from various oligonucleotide-based disciplines including antisense, siRNA, immunomodulatory. About. Incorporated in 2004 as a 501(c)6 nonprofit and registered wi e U.S. government, e Oligonucleotide erapeutics Society is an open, nonprofit forum to foster academia and industry Title: Dedicated to e discovery and . Molecular Types of Oligonucleotide erapeutics 7 miRNA (n= 8-16) siRNA (n= 18-27) Double Strand siRNA, Modified Single, Modified Double Single Strand, miRNA 3’ 5’ 3’ or 5’, Saccharide, Cholesterol, PEG, o er A C G T A C G T A C G T A C G T A C G T 21 FLP = Full Leng Product. mRNA erapeutics. Scientific Platform. Areas of Focus. Science Spotlights. Publications. Our Progress +-Pipeline. Join e Team +-Job Opportunities. Culture. Investors & Media +-Overview. News & Events. Financials and Filings. Corporate Governance. Stock Information. Investor Resources. Contact Us Patients and Families Careers +. Oligonucleotide erapeutics Society. 2,985 likes. 8 talking about. A nonprofit forum to foster academia and industry based research. If you have access to journal via a society or associations, read e instructions below. Oligonucleotide erapeutics: Ann NY Acad Sci 1175, 40 Ciba Found Symp 209, 79. 21, · e next video is starting stop. Loading Watch Queue. e Oligonucleotide erapeutics Society program is delivered rough a four day professional meeting which includes scientific presentations by speakers from industry, academia, and students in e field of oligonucleotide erapeutics. Presentations are presented in general session format and include bo short and long session. TIDES: Oligonucleotide and Peptide erapeutics is an event at consists of two conference EuroTides and EuroPeptides, covering clinical, manufacturing and R&D developments for RNAi, miRNA, Antisense, Aptamers and Peptides.. TIDES: Oligonucleotide and Peptide erapeutics covers topics such as: GalNAc-conjugated siRNAs as a new paradigm in oligonucleotide erapeutics. Review FDA-Approved Oligonucleotide erapies in Cy. Stein 1and Daniela Castanotto 1Department of Medical Oncology and Experimental erapeutics, City of Hope Medical Center, 1500 East Duarte Road, Duarte, CA 9 , USA Oligonucleotides (oligos) have been under clinical develop-ment for approximately e past 30 years, beginning wi anti-. SUWON, Republic of Korea, t. 29, (GLOBE NEWSWIRE) OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi erapeutics, presents two . Save e Dates and register for e e 15 Annual Meeting of e Oligonucleotide erapeutics Society conducted by Oligonucleotide erapeutics Society (OTS) happening on 13 – 16, at Holiday Inn Munchen – Stadtzentrum Hochstraße 3 Munich, Bavaria, Germany Medofocus. Medofocus is one of e largest Medical CME Conferences and Heal care meetings website. A Publication of e American Society for Pharmacology and Experimental erapeutics - ASPET 129 Volume 50 Number 3, 2008 e Pharmacologist Vol. 50 Number 3 2 0 0 8 tember Experimental Biology 2009 ASPET’s Annual Meeting New Orleans, LA April 18 - 22 Program Information Inside! Be sure to join us in e Big Easy! Also Inside is Issue. Oligonucleotide erapeutics Society (OTS) is an open, nonprofit forum to foster academia and industry-based research and develop-ment of oligonucleotide erapeutics. Formed in 2004, OTS is a registered 501(c)6 nonprofit wi e US government. American Association of Pharmaceutical Scientists (AAPS) e American Association of Pharmaceutical. 29, · Meeting Report: Annual Meeting of e Oligonucleotide erapeutics Society. Nucleic Acid er. 24, 428–434 ().Crossref, CAS, Google Scholar. 46 Mergny JL, Lacroix L. Analysis of ermal melting curves. Oligonucleotides 13, 515–537 (2003).Crossref, Medline, CAS, Google Scholar. 47 LeBlanc DA, Morden KM. Quality Assistance attended e 15 Annual Meeting of e Oligonucleotide erapeutics Society (OTS)! e highly regarded annual OTS meeting draws experts from all over e world for cross-disciplinary exchange spanning expertise in chemistry and delivery, to biology, immunology and clinical medicine. Wi more an 35 years’ experience, Quality Assistance has become a leader in analytical. 12, · is outcome offers general lessons for oligonucleotide erapeutics. Pegaptanib was administered directly into e eye (intravitreal administration), revealing a potential streng and opportunity for oligonucleotide erapeutics. Because less material is needed and e dosing is local, costs and e potential for side effects are reduced. We are pleased to announce e six Cold Spring Harbor conference on RNA and Oligonucleotide erapeutics, which will begin at 7:30 pm on Wednesday, ch 27 . CHI is delighted to build on e success of last year’s inural Oligonucleotide CMC and Regulatory Strategies to complement our Discovery and Delivery conference. We bring toge er top scientists and executives from leading biotech and large pharma to share exclusive insights on CMC, manufacturing, analytical and regulatory advancements. Oligonucleotides are characterized by e sequence of nucleotide residues at make up e entire molecule. e leng of e oligonucleotide is usually denoted by -mer (from Greek meros, part). For example, an oligonucleotide of six nucleotides (nt) is a hexamer, while one of 25 nt would usually be called a 25-mer. Oligonucleotide erapeutics: 4 annual meeting Series Annals of e New York Academy of Sciences, 0077-8923 . v. 1175 Note e 2008 annual conference of e Oligonucleotide erapeutics Society took place on ober 15-18 at Harvard Medical School in Boston, sponsored by e New York Academy of Sciences Pref. ISBN 1573317586 9781573317580. DOI: .1200/JCO.2000.18.9.1809 Journal of Clinical Oncology - published online before print 21, . PMID: 784620. 09, · Designing oligonucleotide erapeutics free of complementarity to unintended RNA targets is desirable but almost unrealistic and is analogous to e situation wi small molecule erapies where ey are designed to specifically target a single receptor but interact wi o er related receptors (Lindow et al. ). e specter of ese types. 09, · Nusinersen is an FDA-approved antisense oligonucleotide drug for spinal muscular atrophy 8- at changes e splicing pattern of e SMN2 RNA. 11-13 Reasoning at an antisense oligonucleotide. 06, · Presentation of note: In ober, Moderna presented data from e Phase 1 study of its chikungunya antibody (mRNA-1944) at e Annual Meeting of e Oligonucleotide erapeutics Society. 04, · Oligonucleotides can be characterized by e sequence of nucleotide residues at make up e entire molecule. e leng of e oligonucleotide is usually denoted by ‘’-mer’’. For instance, an oligonucleotide of six nucleotides (nt) is a hexamer, while one of 25 nt would usually be called a 25-mer. Wave recently announced at its lead oph almology program will use stereopure oligonucleotides to promote USH2A exon 13 skipping to address Usher Syndrome Type 2A and presented a poster at e 15 Annual Meeting of e Oligonucleotide erapeutics Society (OTS) titled Stereopure Oligonucleotides at Promote USH2A Exon Skipping for e. Oligonucleotide & Precision erapeutics (OPT Congress) is a conference dedicated to e discovery, development and delivery of oligonucleotide and peptide erapeutics. Oligonucleotide & Precision erapeutics (OPT Congress) covers topics such as: Peptide discovery and delivery - next generation of targeted peptide erapeutics. Apr 01, · ere are few disease-modifying erapeutics for neurodegenerative diseases, but successes on e development of antisense oligonucleotide (ASO) erapeutics for spinal muscular atrophy and Duchenne muscular dystrophy predict a robust future for ASOs in medicine. Indeed, existing pipelines for e development of ASO erapies for spinocerebellar ataxias, Huntington disease, . 07, · is request focuses on oligonucleotide erapeutics designed to hybridize to a cognate RNA to elicit a pharmacologic effect. For all questions, organize any discussion by e type of oligonucleotide erapeutics (e.g., by chemistry or modification type). Please provide e rationale for your suggestions and include supporting data if available. SC1: Oligonucleotide erapeutics: From Discovery to Manufacturing Instructor: Dmitry Sa sky, Ph.D., CSO, Silence erapeutics Additional Instructors to be Announced RNAi/antisense oligonucleotides can target virtually any disease causing gene and promise to become a ird major class of erapeutics (besides small molecules and biologics). Oligonucleotide & Peptide erapeutics E INDUSTRY’S FLAGSHIP MEETING FOR OLIGONUCLEOTIDE AND PEPTIDE SCIENCE, TECHNOLOGY AND NETWORKING NETWORKING SCIENCE TECHNOLOGY Accelerate your pipeline of oligonucleotide and peptide erapeutics to ket by applying best practices and lessons learned from 125+ case studies and new data . 17, · According to Grand View Research, e global antisense and RNAi erapeutics ket size is expected to expand at a compound annual grow rate of 8.6 between and 2025, when it . Oligonucleotide Chemistry, Manufacturing and Controls Peptide Discovery, Preclinical and Clinical Peptide Chemistry Manufacturing and Controls mRNA erapeutics and CRISPR erapeutics Room: Seaport A Room: Seaport BC Room: Balboa ABC Room: La Jolla AB 8:25 am - 12:15 pm Extra-Hepatic Delivery of Oligonucleotides Regulatory Perspectives. 30, · Al ough oligonucleotide erapeutics has been in e development for e last ree ades, only a limited number of drugs have been approved till . 05, · PRECISION-HD1 and PRECISION-HD2 are evaluating investigational WVE-120 1 and WVE-120 2, respectively, which are stereopure oligonucleotides designed to selectively target e mutant huntingtin. RNA & OLIGONUCLEOTIDE ERAPEUTICS April 8 - 11, Abstract Deadline: February 24, . Organizers: Annemieke Aartsma-Rus, Leiden University Medical Center Ar ur Krieg, Checkmate Pharmaceuticals Laura p-Lorenzino, Alnylam Pharmaceuticals Bruce Sullenger, Duke University We are pleased to announce e four Cold Spring Harbor conference on RNA and Oligonucleotide erapeutics.